Anavex Life Sciences (AVXL) Accounts Payables (2011 - 2025)
Anavex Life Sciences recorded quarterly Accounts Payables of $2.6 million in Q4 2025, down 37.89% quarter-over-quarter from $4.2 million in Q3 2025, and down 42.22% year-over-year from $4.6 million in Q4 2024.
Anavex Life Sciences' Accounts Payables history runs 15 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- In Q4 2025, Accounts Payables fell 42.22% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (down 42.22% YoY), while the FY2025 annual figure was $4.2 million, down 55.86% from the prior year.
- Accounts Payables came in at $2.6 million for Q4 2025 at Anavex Life Sciences, down from $4.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $9.6 million in Q3 2024 to a low of $2.6 million in Q1 2022.
- A 5-year average of $4.7 million and a median of $4.3 million in 2023 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables surged 138.68% in 2023 and tumbled 55.86% in 2025, its largest moves.
- Anavex Life Sciences' Accounts Payables stood at $4.6 million in 2021, then rose by 14.1% to $5.3 million in 2022, then dropped by 18.84% to $4.3 million in 2023, then advanced by 6.41% to $4.6 million in 2024, then plunged by 42.22% to $2.6 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $2.6 million, $4.2 million, and $6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.64 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 6.74 Mn |
| Mar 31, 2025 | 7.00 Mn |
| Dec 31, 2024 | 4.57 Mn |
| Sep 30, 2024 | 9.63 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | 4.29 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 4.15 Mn |
| Mar 31, 2023 | 6.28 Mn |
| Dec 31, 2022 | 5.29 Mn |
| Sep 30, 2022 | 3.83 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 4.63 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Jun 30, 2021 | 4.18 Mn |
| Mar 31, 2021 | 3.66 Mn |
| Dec 31, 2020 | 4.22 Mn |
| Sep 30, 2020 | 3.99 Mn |
| Jun 30, 2020 | 3.98 Mn |
| Mar 31, 2020 | 3.65 Mn |
| Dec 31, 2019 | 3.13 Mn |
| Sep 30, 2019 | 3.52 Mn |
| Jun 30, 2019 | 4.34 Mn |
| Mar 31, 2019 | 6.37 Mn |
| Dec 31, 2018 | 4.88 Mn |
| Sep 30, 2018 | 2.96 Mn |
| Jun 30, 2018 | 3.21 Mn |
| Mar 31, 2018 | 3.42 Mn |
| Dec 31, 2017 | 2.80 Mn |
| Sep 30, 2017 | 3.58 Mn |
| Jun 30, 2017 | 1.44 Mn |
| Sep 30, 2016 | 3.12 Mn |
| Jun 30, 2015 | 1.26 Mn |
| Mar 31, 2015 | 1.44 Mn |
| Dec 31, 2014 | 1.32 Mn |
| Sep 30, 2014 | 1.25 Mn |
| Jun 30, 2014 | 1.70 Mn |
| Mar 31, 2014 | 1.69 Mn |
| Dec 31, 2013 | 1.62 Mn |
| Sep 30, 2013 | 1.74 Mn |
| Jun 30, 2013 | 2.80 Mn |
| Mar 31, 2013 | 2.67 Mn |
| Dec 31, 2012 | 2.81 Mn |
| Sep 30, 2012 | 2.59 Mn |
| Jun 30, 2012 | 2.17 Mn |
| Mar 31, 2012 | 1.92 Mn |
| Sep 30, 2011 | 410,024.00 |